ELTX
New analyst, same big biotech dreams
Elicio Therapeutics just picked up a fresh Buy rating from Ladenburg Thalm/SH SH, along with a $20 price target. At the moment, that target implies about 70.5% upside from the stock’s prior close — which is analyst-speak for “we think this thing has room to run.”
The Street is already warming up
This isn’t a lone cowboy call, either. The broader analyst crowd is leaning positive, with a mix that includes one Strong Buy, two Buy ratings, and one Sell, landing the stock at a Moderate Buy consensus and an average target of $18.
Why investors should care
For a smaller biotech like Elicio, fresh coverage can matter almost as much as clinical data on a quiet day. New ratings can boost visibility, bring in new buyers, and give the stock a little more oxygen — especially when the upside math is doing backflips off a low base.
The fine print, because markets love a twist
HC Wainwright also recently bumped its target on Elicio from $13 to $17 and kept a Buy rating. That’s a nice vote of confidence, though the company still reported a $0.49 EPS loss for the quarter, a hair worse than the $0.47 consensus estimate.
Big picture: analysts are nudging the name higher, but biotech investors still have to live and die by the pipeline. Coverage helps — the science has to do the real heavy lifting.